Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: Review of a series of 271 patients with stage I and II breast cancer;L'évaluation conjointe du contenu en ADN et de la fraction de cellules en phase S est un paramètre pronostique indépendant dans les cancers du sein de stades I et II

Cancer/Radiotherapie

Volumn 9, Issue 8, 2005, Pages 575-586

  Moureau Zabotto, L ^a   Bouchet, C ^a   Cesari, D ^a   Uzan, S ^a   Lefranc, J P ^b   Antoine, M ^a   Genestie, C ^b   Deniaud Alexandre, E ^a   Bernaudin, J F ^a   Touboul, E ^a   Fleury Feith, J ^a  

^a HÔPITAL TENON   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Breast cancer; DNA ploidy; S Phase fraction

Indexed keywords

TUMOR MARKER;

ADULT; AGE DISTRIBUTION; ANEUPLOIDY; ARTICLE; BREAST CARCINOMA; CANCER CONTROL; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE S PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIPLOIDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 29144462517     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2005.09.016     Document Type: Article

References (37)

1. D. Amadori, and R. Silvestrini Prognostic and predictive value of thymidine labelling index in breast cancer Breast Cancer Res. Treat. 51 1998 267 281
2. Anonymous Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May, 17, 1996 by the American Society of Clinical Oncology J. Clin. Oncol. 14 1996 2843 2877
3. Anonymous 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November, 7, 1997 by the American Society of Clinical Oncology J. Clin. Oncol. 16 1998 793 795
4. J. Bryant, B. Fisher, N. Gunduz, J. Costantino, and B. Emir S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer Breast Cancer Res. Treat. 51 1998 239 253
5. R.S. Camplejohn, C.M. Ash, C.E. Gillett, B. Raikundalia, D.M. Barnes, and W.M. Gregory The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre Br. J. Cancer 71 1995 140 145
6. R. Charlotte, C.R. Wenger, and G.M. Clark S-phase fraction and breast cancer - a decade of experience Breast Cancer Res. Treat. 51 1998 255 265
7. A. Chassevent, M.L. Jourdan, M. Ferrero-Pous, M. Colonna, S. Romain, and F. Spyratos Standardisation et mise en place d'une assurance qualit́ dans l'́valuation des param̀tres de prolif́ration de 1003 cancers du sein T1T2, N0N1, M0:: ́tude multicentrique II. ADN-ploïdie et phase de synth̀se d'ADN Bull. Cancer 86 1999 685 691
8. A. Chassevent, M.L. Jourdan, S. Romain, F. Descotes, M. Colonna, P.M. Martin for Multicenter Study Group PHRC95 S-phase fraction and DNA ploidy in 633 T1T2 breast cancers a standardized flow cytometric study Clin. Cancer Research. 7 2001 909 917
9. S. Chevillard, J. Lebeau, P. Pouillart, C. de Toma, C. Beldjord, and B. Asselain Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy Clin. Cancer Res. 3 1997 2471 2478
10. G.M. Clark, M.C. Mathieu, M.A. Owens, L.G. Dressler, L. Eudey, and D.C. Tormey Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients J. Clin. Oncol. 10 1992 428 432
11. D.R. Cox Regression models and life tables J R Statist Soc B 34 1972 187 220
12. S. Delaloge, and H. Marsiglia Bases ǵńtiques de la radiosensibilit́ des cancers du sein Cancer Radiother. 9 2005 147 156
13. P. Dettmar, N. Harbeck, C. Thomssen, L. Pache, P. Ziffer, and K. Fizi Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer Br. J. Cancer 75 1997 1525 1533
14. F. Duigou, P. Herlin, J. Marnay, and J.J. Michels Variation of flow cytometric DNA measurement in 1,485 primary breast carcinomas according to guidelines for DNA histogram interpretation Cytometry 42 2000 35 42
15. B. Dutrillaux, M. Gerbault-Seureau, Y. Remvikos, B. Zafrani, and M. Prieur Breast cancer genetic evolution. I. Data from cytogenetics and DNA content Breast Cancer Res. Treat. 19 1991 245 255
16. S.B. Ewers, R. Attewell, B. Baldetorp, A. Borg, E. Langstrom, and D. Killander Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas Breast Cancer Res. Treat. 20 1992 93 108
17. A. Fourquet, B. Cutuli, E. Luporsi, L. Mauriac, J.R. Garbay, and S. Giard Mise ̀ jour des standards, options et recommandations de 2001 pour la radioth́rapie des patientes atteintes d'un cancer du sein infiltrant non ḿtastatique. F́d́ration nationale des centres de lutte contre le cancer (FNCLCC) Cancer Radiother. 6 2002 238 258
18. M.F. Gnant, G.H. Blijham, A. Reiner, M. Schemper, M. Reynders, and B. Schutte DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10-year results of a randomised study Eur. J. Cancer 28 1992 711 716
19. A. Goldhirsch, J.H. Glick, R.D. Gelber, and H.J. Senn Meeting highlights: international consensus panel on the treatment of primary breast cancer J. Natl. Cancer Inst. 90 1998 1601 1608
20. O.P. Kallioniemi, G. Blanco, M. Alavaikko, T. Hietanen, J. Mattila, and K. Lauslahti Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer Cancer 61 1988 2183 2190
21. E.S. Kaplan, and P. Meier Non parametric estimation from incomplete observations Am. Stat. Assoc. J. 53 1958 457 480
22. T.E. Kute, Y. Quadri, H. Muss, N. Zbieranski, C. Cirrincione, and D.A. Berry Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869 Cytometry 22 1995 297 306
23. R. Largillier, M. Namer, A. Ramaioli, J.M. Ferrero, N. Magne, and A. Courdi Prognostic value of S-phase fraction in 920 breast cancer patients: focus on T1N0 status Int. J. Biol. Markers 18 2003 273 279
24. J.J. Michels, J. Marnay, T. Delozier, Y. Denoux, and J. Chasle Proliferative activity in primary breast carcinomas is a salient prognostic factor Cancer 100 2004 455 464
25. S.M. O'Reilly, R.S. Camplejohn, D.M. Barnes, R.R. Millis, R.D. Rubens, and M.A. Richards Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry J. Clin. Oncol. 8 1990 2040 2046
26. S.M. O'Reilly, R.S. Camplejohn, D.M. Barnes, R.R. Millis, D. Allen, and R.D. Rubens DNA index, S-phase fraction, histological grade and prognosis in breast cancer Br. J. Cancer 61 1990 671 674
27. Y. Remvikos, V. Mosseri, B. Asselain, A. Fourquet, J.C. Durand, and P. Pouillart S-phase fractions of breast cancer predict overall and post-relapse survival Eur. J. Cancer 33 1997 581 586
28. S. Romain, I.J. Christensen, O. Chinot, I. Balslev, C. Rose, and P.M. Martin Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer Int. J. Cancer 61 1995 7 12
29. P. Rudolph, P. Alm, H.J. Heidebrecht, H. Bolte, V. Ratjen, and B. Baldetorp Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer J. Natl. Cancer Inst. 91 1999 271 278
30. T.V. Shankey, P.S. Rabinovitch, B. Bagwell, K.D. Bauer, R.E. Duque, and D.W. Hedley Guidelines for implementation of clinical DNA cytometry Cytometry 14 1993 472 477
31. R. Silvestrini, M.G. Daidone, A. Luisi, M. Mastore, M. Leutner, and B. Salvadori Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index Int. J. Cancer 74 1997 122 127
32. J.F. Simpson, R. Gray, L.G. Dressler, C.D. Cobau, C.I. Falkson, and K.W. Gilchrist Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the eastern cooperative oncology group companion study, EST 4189 J. Clin. Oncol. 18 2000 2059 2069
33. F. Spyratos, M. Briffod, M. Tubiana-Hulin, C. Andrieu, C. Mayras, and C. Pallud Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up Cancer 69 1992 470 475
34. F. Spyratos, P.M. Martin, K. Hacene, S. Romain, C. Andrieu, and M. Ferrero-Pous Multiparametric prognostic evaluation of biological factors in primary breast cancer J. Natl. Cancer Inst. 84 1992 1266 1272
35. O. Stal, L. Skoog, L.E. Rutqvist, J.M. Carstensen, S. Wingren, and S. Sullivan S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer Br. J. Cancer 70 1994 1258 1262
36. A.D. Thor, S. Liu, D.H. Moore, and S.M. Edgerton Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer J. Clin. Oncol. 17 1999 470 477
37. C.R. Wenger, and G.M. Clark S-phase fraction and breast cancer: a decade of experience Breast Cancer Res. Treat. 51 1998 255 265